Maher, T. M., Tudor, V. A., Saunders, P., Gibbons, M. A., Fletcher, S. V., Denton, C. P., Hoyles, R. K., Parfrey, H., Renzoni, E. A., Kokosi, M., Wells, A. U., Ashby, D., Szigeti, M., Molyneaux, P. L., , , Akil, M., Babalis, D., Chaudhuri, N., Chua, F., Data, A., Desai, D., Dubey, S., Dwyer, N., Flather, M., Fordham, R., Grossi Sampedro, C., Hall, F., Jakupovic, I., Keir, G., Patel, B., Penn, H., Rajasekaran, A., Spencer, L. G., Tsipouri, V., Wu, Z., Xydopoulos, G., & Zanghelini, F. (2023). rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet, 11(1), 45–54. http://access.bl.uk/ark:/81055/vdc_100173090117.0x00000f